Get the Stockscreener App
14.32
0.00%
0.00
After Hours:
14.32
Keros Therapeutics Inc stock is traded at $14.32, with a volume of 260.98K.
It is up +0.00% in the last 24 hours and up +7.35% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$14.32
Open:
$14.31
24h Volume:
260.98K
Relative Volume:
0.45
Market Cap:
$581.61M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-2.7914
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
-0.97%
1M Performance:
+7.35%
6M Performance:
+25.61%
1Y Performance:
-71.56%
1-Day Range:
$14.25
$14.50
1-Week Range:
$14.25
$14.81
52-Week Range:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
14.32 | 581.61M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
What is the risk reward ratio of investing in Keros Therapeutics Inc. stockTop Growth Tips For Consistent Profits - jammulinksnews.com
Corton Capital Inc. Invests $186,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Keros Therapeutics Inc. stock overvalued or undervaluedLow Risk Recommendation That Work - jammulinksnews.com
Can Keros Therapeutics Inc. Outperform Peers After Recent PullbackEarly Entry Tips With Low Risk Zone Shared - metal.it
Bollinger Bands Show Potential Breakout in Keros Therapeutics Inc.AI Screening for Swing Trade Picks Finds Momentum - metal.it
What makes Keros Therapeutics Inc. stock price move sharplyPre Market Trend Scanner From AI Tools - jammulinksnews.com
How strong is Keros Therapeutics Inc. company’s balance sheetBuild wealth steadily with smart trading - jammulinksnews.com
What are Keros Therapeutics Inc. company’s key revenue driversHigh-performance investment picks - jammulinksnews.com
Is it the right time to buy Keros Therapeutics Inc. stockFree AI-Backed Trading Signals - jammulinksnews.com
Is Keros Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideShort Term High Return Strategy - metal.it
What catalysts could drive Keros Therapeutics Inc. stock higher in 2025Invest smarter with real-time trading signals - jammulinksnews.com
Published on: 2025-07-27 21:20:25 - jammulinksnews.com
What are analysts’ price targets for Keros Therapeutics Inc. in the next 12 monthsInvest like a pro with expert recommendations - jammulinksnews.com
Why Keros Therapeutics Inc. stock attracts strong analyst attentionStrong Return Daily Alerts - metal.it
What drives Keros Therapeutics Inc. stock priceExceptional ROI - PrintWeekIndia
What analysts say about Keros Therapeutics Inc. stockTremendous return on equity - PrintWeekIndia
Is Keros Therapeutics Inc. a good long term investmentRapid-fire capital growth - PrintWeekIndia
How high can Keros Therapeutics Inc. stock price go in 2025Fast-track wealth growth - jammulinksnews.com
Keros Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Real-Time Monitoring - jammulinksnews.com
(KROS) Trading Signals - news.stocktradersdaily.com
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Keros Therapeutics Inc Stock (KROS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
| GORDON CARL L | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):